• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Melanoma Drug Pipeline Update 2014 Product Image

Melanoma Drug Pipeline Update 2014

  • ID: 1196711
  • October 2014
  • Region: Global
  • Bioseeker

Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.
There are today 263 companies plus partners developing 318 drugs targeting melanoma in development. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 139 drugs. Melanoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 271 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 254 out of the 257 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 59 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline READ MORE >

Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Our clients' logos